Results 31 to 40 of about 89,537 (296)

JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. [PDF]

PLoS ONE, 2015
Constitutive activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) axis is fundamental to the molecular pathogenesis of a host of hematological disorders, including acute leukemias and myeloproliferative neoplasms ...
Jun Guo, Lisa Roberts, Zhui Chen, Philip J Merta, Keith B Glaser, O Jameel Shah   +5 more
doaj   +1 more source

JAK-STAT pathway inhibitors in dermatology

Anais Brasileiros de Dermatologia, 2023
The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions.
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, Mayra Ianhez, Carolina Talhari, Paulo Müller Ramos   +5 more
openaire   +4 more sources

JAK inhibitors: Ten years after

European Journal of Immunology, 2021
AbstractThe European Journal of Immunology was launched 50 years ago, coinciding with the discovery of many cytokines and growth factors and the emergence of an entirely new field of research. Ultimately, our knowledge about the biological activity of these factors allowed us to better understand how the immune system functions in the context of ...
Spinelli, Francesca Romana, Meylan, Françoise, O'Shea, John J., Gadina, Massimo   +3 more
openaire   +5 more sources

Pulmonary nodules associated with JAK inhibitor therapy in rheumatoid arthritis [PDF]

, 2021
Patients with rheumatoid arthritis (RA) may receive Janus kinase (JAK) inhibitors to achieve optimal control of their disease. We report a case of a patient who received a selective JAK1 inhibitor and subsequently developed multiple pulmonary nodules ...
Tintinger, Gregory Ronald, Ally, Mahmood Moosa Tar Mahomed, Pannell, N., Bida, Nndweleni Meshack, Joseph, Darren   +4 more
core   +1 more source

Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis

, 2023
The JAK kinases JAK1, JAK2, JAK3, and TYK2 play key roles in cytokine signaling. Activation of the JAK/STAT pathways is linked to many diseases involving the immune system, including atopic dermatitis. As systemic JAK inhibitor pharmacology is associated
Shaila Hoque (14477737), Sandro Bruno (14477725), Ulrike Strittmatter-Keller (6078497), Kerri Grove (14477734), Patrick J. Rudewicz (8081681), Sabine Viebrock (14477731), Hans-Guenter Zerwes (2720452), Rudolf O. Duthaler (2986965), Rudolf Waelchli (7376636), Alice Hauchard (14477722), Reiner Aichholz (2504137), Gebhard Thoma (2238247), Anette Orjuela Leon (14477728), Karen Beltz (8784746)   +13 more
core   +3 more sources

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience [PDF]

, 2023
Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheuma-toid arthritis (RA) and provides improvements in clinical signs ...
Alten, Rieke, Feist, Eugen, Choy, Ernest, Taylor, Peter C, Laedermann, Cedric, Finckh, Axel, Haladyj, Ewa, De La Torre, Inmaculada, Richette, Pascal, Tanaka, Yoshiya   +9 more
core   +2 more sources

A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus

Journal of Pharmacological Sciences, 2021
Systemic lupus erythematosus is a chronic inflammatory disease, in which treatment is still limited due to suboptimal efficacy and toxicities associated with the available therapies.
Maria Dulak-Lis, Anna Bujak, Kamila Gala, Martyna Banach, Urszula Kędzierska, Joanna Miszkiel, Joanna Hucz-Kalitowska, Michał Mroczkiewicz, Bartosz Stypik, Krzysztof Szymczak, Paweł Gunerka, Krzysztof Dubiel, Beata M. Zygmunt, Maciej Wieczorek, Jerzy S. Pieczykolan   +14 more
doaj   +1 more source

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy [PDF]

Journal of Immunotherapy and Precision Oncology, 2021
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders that consist classically of polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).
Sophia S. Lee, Srdan Verstovsek, Naveen Pemmaraju   +2 more
doaj   +1 more source

Increased STAT1 signaling in endocrine-resistant breast cancer [PDF]

, 2014
Funding: China Scholarship Council, University of Edinburgh, Scottish Funding Council and Breakthrough Breast Cancer.Proteomic profiling of the estrogen/tamoxifen-sensitive MCF-7 cell line and its partially sensitive (MCF-7/LCC1) and fully resistant (MCF-
Thomas Jeremy S., Faratian Dana, Huang Rui, Sims Andrew H., Dana Faratian (171110), Simon P. Langdon, Danielle Wilson (550968), David J. Harrison (171106), Jeremy S. Thomas, Dana Faratian, Rui Huang, Wilson Danielle, Harrison David J., David J. Harrison, Danielle Wilson, Simon P Langdon, Thomas, Jeremy S, Sims, Andrew H, Andrew H. Sims (108040), Harrison, David J, Rui Huang (141490), Huang, Rui, Simon P. Langdon (207293), Wilson, Danielle, David J Harrison, Thomas, Jeremy, Langdon Simon P., Faratian, Dana, Andrew H. Sims, Andrew H Sims, Jeremy S Thomas, Jeremy S. Thomas (550969), Langdon, Simon P   +32 more
core   +1 more source

1H NMR Study on Serum Metabonomic Alterations Induced by JAK/STAT Pathway Inhibitor in C57BL/6 Mice

Chinese Journal of Magnetic Resonance, 2018
JAK/STAT pathway inhibitor has been used in clinic trial for several diseases. However, the adverse effect of systematic administration of JAK/STAT pathway inhibitors on cellular function is largely unknown.
ZHAO Xin, XIAO Xiong-jie, GAO Dong-li, ZHANG Xian-rong   +3 more
doaj   +1 more source